Vertex Shares Downgraded at Oppenheimer Due to Uncertainties in LSR Trial
Daily NewsOppenheimer downgraded Vertex Pharmaceuticals’ rating after announcing Phase 2 trial results for suzetrigine in the treatment of painful lumbosacral radiculopathy...
Read More